Literature DB >> 27573894

MicroRNAs and Inflammation in Colorectal Cancer.

Claire Josse1, Vincent Bours2.   

Abstract

Colorectal cancers (CRC) are known to be related to inflammatory conditions, and inflammatory bowel diseases increase the relative risk for developing CRC. The use of anti-inflammatory drugs prevents the development of colorectal cancer.Several molecular mediators are connecting the pathways that are involved in inflammatory conditions and in carcinogenesis. By the way these pathways are tightly interwoven, with the consequence that a deregulation at the level of any of these molecular mediators can affect the others.MiRNAs are demonstrated to be deregulated in inflammatory bowel diseases and in colorectal cancer. Moreover, they target several molecular mediators that connect inflammation to cancer, and they are thus implicated in the route from inflammation to colorectal cancer.This chapter will focus on the miRNAs that are jointly deregulated in inflammatory bowel disease and in colorectal cancer. Their role on the regulation of the molecular mediators and pathways that link inflammation to cancer will be described.

Entities:  

Keywords:  CAC; Colorectal cancer; IBD; Inflammation; Inflammatory bowel disease; microRNAs

Mesh:

Substances:

Year:  2016        PMID: 27573894     DOI: 10.1007/978-3-319-42059-2_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  13 in total

1.  Targeting microRNA/UHRF1 pathways as a novel strategy for cancer therapy.

Authors:  Hani Choudhry; Mazin A Zamzami; Ziad Omran; Wei Wu; Marc Mousli; Christian Bronner; Mahmoud Alhosin
Journal:  Oncol Lett       Date:  2017-10-30       Impact factor: 2.967

2.  miR-302b inhibits cancer-related inflammation by targeting ERBB4, IRF2 and CXCR4 in esophageal cancer.

Authors:  Mingxin Zhang; Lingmin Zhang; Manli Cui; Wenguang Ye; Pengjiang Zhang; Suna Zhou; Jingjie Wang
Journal:  Oncotarget       Date:  2017-07-25

Review 3.  Inflammatory Markers and MicroRNAs: The Backstage Actors Influencing Prognosis in Colorectal Cancer Patients.

Authors:  Rihab Nasr; Miza Salim Hammoud; Farah Nassar; Deborah Mukherji; Ali Shamseddine; Sally Temraz
Journal:  Int J Mol Sci       Date:  2018-06-26       Impact factor: 5.923

4.  Mir-124 Attenuates STAT3-Mediated TH17 Differentiation in Colitis-Driven Colon Cancer.

Authors:  Shiyong Lin; Qianwen Liu; Jing Wen; Kunhao Bai; Yandong Guo; Jing Wang
Journal:  Front Oncol       Date:  2020-12-17       Impact factor: 6.244

Review 5.  Revisiting cancer hallmarks: insights from the interplay between oxidative stress and non-coding RNAs.

Authors:  Li Zhou; Zhe Zhang; Zhao Huang; Edouard Nice; Bingwen Zou; Canhua Huang
Journal:  Mol Biomed       Date:  2020-08-31

6.  Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study.

Authors:  Xinrong Zhang; Vincent Wai-Sun Wong; Terry Cheuk-Fung Yip; Yee-Kit Tse; Lilian Yan Liang; Vicki Wing-Ki Hui; Guan-Lin Li; Henry Lik-Yuen Chan; Grace Lai-Hung Wong
Journal:  Hepatol Commun       Date:  2021-03-21

7.  Profiling the lncRNA-miRNA-mRNA ceRNA network to reveal potential crosstalk between inflammatory bowel disease and colorectal cancer.

Authors:  Fangfang Sun; Weiwei Liang; Kejun Tang; Mengying Hong; Jing Qian
Journal:  PeerJ       Date:  2019-08-26       Impact factor: 2.984

Review 8.  MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer.

Authors:  Jaslin P James; Lene Buhl Riis; Mikkel Malham; Estrid Høgdall; Ebbe Langholz; Boye S Nielsen
Journal:  Int J Mol Sci       Date:  2020-10-24       Impact factor: 5.923

Review 9.  TLR4 signaling in the development of colitis-associated cancer and its possible interplay with microRNA-155.

Authors:  Jie Guo; Mengfan Liao; Jun Wang
Journal:  Cell Commun Signal       Date:  2021-09-03       Impact factor: 5.712

10.  miR-142-3p Modulates Cell Invasion and Migration via PKM2-Mediated Aerobic Glycolysis in Colorectal Cancer.

Authors:  JunYu Ren; Wenliang Li; Guoqing Pan; Fengchang Huang; Jun Yang; Hongbin Zhang; Ruize Zhou; Ning Xu
Journal:  Anal Cell Pathol (Amst)       Date:  2021-07-13       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.